| Literature DB >> 27028036 |
Sibylle De Germay1,2,3, Jean-Louis Montastruc1,2,3,4,5, Vanessa Rousseau1,2,3,4, Leila Chebane1,2, Emmanuelle Bondon-Guitton1,2,3, Florence Moulis1,2, Genevieve Durrieu1,2, Haleh Bagheri1,2,3,5, Olivier Rascol1,4,5,6, Antoine Pariente7,8, Bernard Bégaud7,8, François Montastruc1,2,3,4,5,7.
Abstract
Use of atropinic drugs remains controversial in Parkinson's disease (PD) because there is insufficient evidence about their efficacy and they can induce serious adverse drug reactions. Atropinic risk scales were developed to help to identify atropinic drugs in prescription forms and to evaluate their burden in clinical practice. In the present review, we discuss the few studies investigating atropinic burden in PD and present the results of our study indicating that atropinic drugs are still widely prescribed in PD (almost 3 of 5 prescriptions) with a clinically significant atropinic burden in around 1 of 6 PD patients. Drugs mainly responsible for high values of atropinic burden were those used for nonmotor symptoms. Clinically significant atropinic burdens were mainly induced by associations of several "low-risk" drugs. Physicians must be aware that in addition to classical atropinic antiparkinsonian drugs, many others (psychotropics) can contribute to increased atropinic burden in PD patients.Entities:
Keywords: Parkinson's disease; anticholinergic burden; anticholinergic drugs; atropinic burden; atropinic drugs
Mesh：
Substances：
Year: 2016 PMID： 27028036 DOI： 10.1002/mds.26595
Source DB: PubMed Journal: Mov Disord ISSN： 0885-3185 Impact factor: 10.338